GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
Key Highlights
- ➤Vanina Popova appointed Chief Development Officer to lead GH001’s pivotal programs
- ➤GH001 targets pivotal programs in treatment-resistant and postpartum depression
- ➤Popova brings over 20 years of Johnson & Johnson pharmaceutical R&D experience
- ➤GH001 Phase 2b trial met its primary endpoint with a -15.5 MADRS reduction
- ➤GH001 showed a placebo comparison of p<0.0001 on Day 8
Expert Statements
Velichka Valcheva, Chief Executive Officer of GH Research PLC
“We are very pleased to appoint Vanina as our Chief Development Officer. She brings extensive experience and insight from late-stage clinical development in TRD.”
Vanina Popova, Chief Development Officer of GH Research PLC
“I have spent much of my career working to bring new treatments to people living with depression, and I know how many patients are still not helped by the options available today. The clinical results with GH001, and its potential to address this significant unmet need, are what drew me to GH Research. I look forward to leading the next stage of clinical development as we take GH001 into pivotal programs in TRD and PPD.”
* Dr. Popova will lead the clinical development of GH001 as the company advances toward pivotal programs in TRD and PPD * Brings more than 20 years of global pharmaceutical R&D experience at Johnson & Johnson across clinical operations, clinical development, regulatory strategy, and neuroscience portfolio leadership * Clinical lead in the Spravato® (esketamine) program, where she led TRANSFORM-2, one of the pivotal Phase 3 trials that supported its approval in TRD, and was lead author of the trial publication DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression (TRD) and postpartum depression (PPD).
Get started
Create a free account to read the full story.